| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA972: sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal) |
|
Medicine details |
|
| Medicine name | sirolimus (Hyftor®) |
| Formulation | 2 mg/g gel |
| Reference number | 6300 |
| Indication | Treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older. |
| Company | Plusultra pharma |
| BNF chapter | Skin |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 22/10/2024 |
| NICE guidance | |